- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OPTIMIND PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.03. | Optimind Pharma Corp: Optimind Pharma resuming at the open | 1 | Stockwatch | ||
| 25.03. | Optimind Pharma Corp: Optimind enters LOI to acquire Monjin Interviews | 3 | Stockwatch | ||
| 25.03. | Optimind Pharma Corp.: Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business | 586 | Newsfile | Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March... ► Artikel lesen | |
| 21.03. | Optimind Pharma Corp: Optimind Pharma halted at 10:41 a.m. PT | 1 | Stockwatch | ||
| 29.07.24 | Optimind Pharma Corp.: Optimind Pharma Closes Second Tranche of Private Placement | 197 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the second trance of its previously announced private placement.... ► Artikel lesen | |
| 08.07.24 | Optimind Pharma Corp.: Optimind Pharma Closes First Tranche of Private Placement | 412 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the first trance of its previously announced private placement.... ► Artikel lesen | |
| 03.07.24 | Optimind Pharma Corp.: Optimind Pharma - Private Placement | 677 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces a proposed private placement. The Company intends to issue up to 10... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 59,22 | -0,07 % | Aktien Europa: Zollhoffnungen liefern weiter Rückenwind - Ölwerte gefragt | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die europäischen Börsen haben am Freitag ihre Vortagesgewinnne leicht ausgebaut. "Das Handelsstreitthema bleibt weiterhin marktbeherrschend und so konnte das Handelsabkommen... ► Artikel lesen | |
| AURORA CANNABIS | 4,455 | +0,56 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| CANOPY GROWTH | 1,202 | +0,84 % | Starke Zahlen, Aktie steigt: Nicht Canopy Growth: Diese Cannabis-Aktie gibt es jetzt umsonst! | © Foto: Dall-EDas Cannabisunternehmen Cronos hat am Donnerstagmittag starke Quartalszahlen vorgelegt - und im Unterschied zu Canopy Growth einen Nettogewinn erzielt.Innerhalb der Cannabis-Branche gilt... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,032 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
| SINOPHARM | 2,101 | -1,73 % | Sinopharm Group-Aktie kann Vortagsniveau nicht halten (2,006 €) | Am Aktienmarkt notiert die Sinopharm Group-Aktie gegenwärtig etwas leichter. Das Papier notiert zur Stunde bei 2,01 Euro. Für Inhaber der Sinopharm Group ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 3,820 | +7,30 % | JMP cuts Astria Therapeutics target to $25, maintains rating | ||
| CSPC PHARMA | 0,639 | -3,50 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION | ||
| TONIX PHARMACEUTICALS | 20,200 | -1,94 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 1,952 | -3,63 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
| ADASTRA | 0,177 | 0,00 % | Adastra Holdings Ltd.: Adastra Holdings Announces New Director | Langley, British Columbia--(Newsfile Corp. - March 3, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 92,84 | -3,21 % | Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone | WASHINGTON (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced that it has entered into a $570 million term loan and revolving credit facility with funds managed... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,250 | -2,39 % | Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program | Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May... ► Artikel lesen | |
| ALTIMMUNE | 5,134 | -0,58 % | Piper Sandler maintains Altimmune stock with $25 target | ||
| SELLAS LIFE SCIENCES | 1,436 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML | NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of... ► Artikel lesen |
Das Unternehmen OPTIMIND PHARMA CORP kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTIMIND PHARMA CORP finden Sie auf Wallstreet Online.